💼 Business 4h ago · Hilary Brueck

Sam Altman's longevity company is testing an extra-strength Alzheimer's drug after disappointing trial results

Business Insider
Deep dives into tech, finance, and strategy
View Channel →
Sam Altman's longevity company is testing an extra-strength Alzheimer's drug after disappointing trial results
Source ↗ 👁 0 💬 0
The Sam Altman-backed longevity biotech company is upping the dose of its experimental Alzheimer's drug in clinical trials.

Comments (0)

Sign in to join the discussion

More Like This

Meta's $18bn settlement a landmark victory for US states
BBC News · 2h ago
I need to get out of my job, but I’ve signed a noncompete. Can I still leave for a competitor?
MarketWatch.com - Top Stories · 2h ago
📰
Boring Co.’s Vegas Loop announces approval of 19 additional stations, bringing total to 123
Las Vegas Business News & Updates · 2h ago
Revolution’s lifesaving pancreatic cancer drug wins speedy FDA approval
All News · 2h ago
Two-thirds of parents are failing at this vital safety measure for their children
MarketWatch.com - Top Stories · 2h ago
Meta agrees to pay $18 billion to settle lawsuits over children’s social media addiction
All News · 2h ago